American Association for Cancer Research

AACR Statement on Proposed Medicare Coverage of Erythropoiesis Stimulating Agents (ESAs)

The American Association for Cancer Research, the world's oldest and largest organization dedicated to cancer research, submitted comments this week to the Centers for Medicare and Medicaid Services (CMS) expressing concern regarding the agency's proposed national coverage policy that would govern Medicare coverage of ESAs in cancer and related neoplastic conditions. The comments submitted express AACR's concerns regarding the lack of sound scientific and clinical data to support certain conditions of the proposed decision memorandum and provide a brief analysis of the existing data on this subject. A complete copy of AACR's comments can be found online. CMS has up to 60 days to review the comments and additional evidence. Thereafter, they will issue a final decision. AACR plans to meet with CMS during this time to discuss concerns and work with CMS to evaluate the evidence.